1
|
Niu ZL, Zhang PA, Tong YQ. Association of plasma interleukin-18 levels and polymorphisms in interleukin-18 gene with outcomes of hepatitis C virus infections: a meta-analysis. J Immunoassay Immunochem 2015; 36:221-32. [PMID: 24906108 DOI: 10.1080/15321819.2014.924418] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Several polymorphisms in the interleukin-18 (IL-18) gene and plasma IL-18 levels have been reported to influence hepatitis C virus (HCV) infection. However, the published findings have been conflicting. We conducted meta-analyses of randomized, controlled trials to address the association of IL-18 polymorphisms and plasma IL-18 levels and the outcomes of HCV infection. The results showed that there was no evidence for an association between the HCV infections and the polymorphisms genotypes of IL-18. However, plasma IL-18 levels were found higher in HCV infection patients than in healthy controls. The pooled SMD was 2.911(95% CI 2.556-3.265, z = 16.09, P < 0.001).
Collapse
Affiliation(s)
- Zhi Li Niu
- a Department of Laboratory Science , Renmin Hospital of Wuhan University , Wuhan , China
| | | | | |
Collapse
|
2
|
Ishii K, Shinohara M, Kogame M, Shiratori M, Higami K, Kanayama K, Shiozawa K, Wakui N, Nagai H, Watanabe M, Sumino Y. Effects of mutation number in interferon sensitivity determining region on peripheral blood CD4(+) T cell subsets (Th1, Th2) in chronic hepatitis C patients with hepatitis C virus genotype 1b and high viral load. Hepatol Int 2011; 6:468-74. [PMID: 21818686 DOI: 10.1007/s12072-011-9305-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/02/2011] [Accepted: 07/18/2011] [Indexed: 12/25/2022]
Abstract
BACKGROUND/AIM The number of amino acid (AA) mutations in the interferon sensitivity determining region (ISDR) of NS5A is reported to affect the response to interferon (IFN) therapy in patients with chronic hepatitis C (CHC). The aim of this study was to clarify whether host immunity is influenced by the number of AA mutations in the ISDR. PATIENTS AND METHODS Subjects included 44 patients with CHC infected with genotype 1b and high viral load. The number of AA mutations in the ISDR was retrospectively determined using stored serum samples taken immediately before starting therapy. All patients received IFN-alpha 2b or pegylated-IFN (PEG-IFN)-alpha 2b and ribavirin. When serum hepatitis C virus-ribonucleic acid (HCV-RNA) was negative at 4 or 12 weeks after starting therapy, the patient was defined as having rapid viral response (RVR) or early viral response (EVR), respectively. CD4(+) T cell (Th1 or Th2) in peripheral blood (PB) before and until day 56 of treatment was analyzed. RESULTS Rates of RVR and EVR were 0 (0/21) and 14% (3/21), respectively, in patients with one or fewer AA mutations in the ISDR (ISDR0-1), and 30 (7/23), and 74% (17/23), respectively, with two or more AA mutations in the ISDR (ISDR > 2). Although the percentage of PB Th1 cells did not differ between the two groups during the study period, the percentage of PB Th2 cells was significantly lower in the ISDR0-1 group than in the ISDR > 2 group at baseline and on days 3, 7, 14, and 28 of treatment. CONCLUSION The number of AA mutations in the ISDR influenced PB Th2 cells before and until day 28, and was associated with higher RVR and EVR rates.
Collapse
Affiliation(s)
- Koji Ishii
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, 6-11-1, Omorinishi, Otaku, Tokyo, 143-8541, Japan.
| | - Mie Shinohara
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, 6-11-1, Omorinishi, Otaku, Tokyo, 143-8541, Japan
| | - Michio Kogame
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, 6-11-1, Omorinishi, Otaku, Tokyo, 143-8541, Japan
| | - Misato Shiratori
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, 6-11-1, Omorinishi, Otaku, Tokyo, 143-8541, Japan
| | - Katsuya Higami
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, 6-11-1, Omorinishi, Otaku, Tokyo, 143-8541, Japan
| | - Kaori Kanayama
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, 6-11-1, Omorinishi, Otaku, Tokyo, 143-8541, Japan
| | - Kazue Shiozawa
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, 6-11-1, Omorinishi, Otaku, Tokyo, 143-8541, Japan
| | - Noritaka Wakui
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, 6-11-1, Omorinishi, Otaku, Tokyo, 143-8541, Japan
| | - Hidenari Nagai
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, 6-11-1, Omorinishi, Otaku, Tokyo, 143-8541, Japan
| | - Manabu Watanabe
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, 6-11-1, Omorinishi, Otaku, Tokyo, 143-8541, Japan
| | - Yasukiyo Sumino
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Toho University School of Medicine, 6-11-1, Omorinishi, Otaku, Tokyo, 143-8541, Japan
| |
Collapse
|
4
|
Bouzgarrou N, Hassen E, Schvoerer E, Stoll-Keller F, Bahri O, Gabbouj S, Cheikh I, Maamouri N, Mammi N, Saffar H, Trabelsi A, Triki H, Chouchane L. Association of interleukin-18 polymorphisms and plasma level with the outcome of chronic HCV infection. J Med Virol 2008; 80:607-14. [PMID: 18297714 DOI: 10.1002/jmv.21079] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Hepatitis C virus (HCV) infection is the main cause of chronic liver disease throughout the world, and may progress to cirrhosis and hepatocellular carcinoma (HCC). Immunological factors, especially cytokines and some host genetic variations, rather than direct HCV action, seem to play an important role in the pathogenesis of HCV infection. Elevated levels of interleukin-18 (IL-18) were described previously for chronically (HCV)-infected patients. This study is aimed at investigating IL-18 promoter polymorphisms (-607C/A and -137G/C) in HCV-infected patients with different disease severities (chronic hepatitis C, liver cirrhosis and HCC) and establishing an association between these polymorphisms and IL-18 plasma concentration with the outcome of chronic HCV infection. The carriage of at least one C allele at position -607 (CC + CA) was associated with a higher risk of cirrhosis and HCC (P = 0.032). Compared with controls, HCV-infected patients had significantly higher levels of IL-18 (P = 0.0001) that correlate with disease severity (P = 0.01, P = 0.001, P = 0.0006, respectively). In conclusion, we supposed a possible implication of IL-18 promoter polymorphisms in the pathogenesis of chronic HCV infection.
Collapse
Affiliation(s)
- N Bouzgarrou
- Laboratory of Molecular Immuno-oncology, Faculty of Medicine, Monastir, Tunisia.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Schvoerer E, Navas MC, Thumann C, Fuchs A, Meyer N, Habersetzer F, Stoll-Keller F. Production of interleukin-18 and interleukin-12 in patients suffering from chronic hepatitis C virus infection before antiviral therapy. J Med Virol 2003; 70:588-93. [PMID: 12794721 DOI: 10.1002/jmv.10434] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Interleukin-12 and -18 (IL-12 and IL-18) are known to enhance the cytotoxic T-lymphocyte response synergistically, but their precise involvement in hepatitis C virus (HCV) infection is not well known, especially for IL-18. Enzyme-linked immunosorbent assay (ELISA) was used to study the production of these cytokines in plasma and peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide (LPS) of patients infected chronically with HCV before initiation of antiviral therapy. Fifty-six patients and 40 healthy controls were evaluated. Patients infected with genotype 1 or with genotype other than genotype 1 HCV had significantly a high production of plasma IL-12 compared with controls (P < 0.05). However, patients infected with genotype 1 HCV had lower levels of PBMC IL-18 than were founded in the controls (P < 0.05); plasma IL-18 also tended to be lower in this group of patients than in the controls, although nonsignificantly. Plasma IL-18 was related to hepatic histological activity (P < 0.05). The data suggest a relationship between these two cytokines and some features of HCV infection, so that their respective production in relation to the outcome of the infection deserves further study.
Collapse
Affiliation(s)
- E Schvoerer
- Institut de Virologie et Unité INSERM 544, Université Louis Pasteur, Strasbourg, France.
| | | | | | | | | | | | | |
Collapse
|